IP Library Granted Patent US 8,501,195
Granted Patent B2
US 8,501,195 · App. 13/075,485 · Granted Aug 6, 2013

Injection paradigm for administration of botulinum toxins

Inventors: Catherine C. Turkel (Newport Coast, CA); Mitchell F. Brin (Newport Beach, CA); Sheena K. Aurora (Seattle, WA); David W. Dodick (Scottsdale, AZ)
Assignee: Allergan, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,501,195
App. No.
13/075,485
Granted
Aug 6, 2013
Kind
B2
Abstract

Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.

Claims (8)

1. A method for treating or reducing the occurrence of a headache in a patient with chronic migraine headaches, the method consisting of:

local administration of a botulinum neurotoxin to the frontalis, corrugator, procereus, occipitalis, temporalis, trapezius and cervical paraspinal muscles of the patient that suffers from the migraine headache;

wherein the botulinum neurotoxin is administered, to the frontalis at about twenty units divided among four sites of injection; to the corrugator at about ten units divided among two sites of injection; to the procerus at about five units to one site of injection; to the occipitalis at about thirty units divided among six sites of injection to about forty units divided among eight sites of injection; to the temporalis at about forty units divided among eight sites of injection up to fifty units divided among ten sites of injection; to the trapezius at about thirty units divided among six sites of injection up to about fifty units divided among ten sites of injection and to the cervical paraspinal muscles at about twenty units divided among four sites of injection;

wherein the botulinum neurotoxin is injected at 31 to 39 injection sites.

2. The method of claim 1 wherein the total amount of botulinum neurotoxin administered is from about 155 units to about 195 units of onabotulinumtoxinA.

3. The method of claim 1 wherein the botulinum neurotoxin is type B.

4. The method of claim 1 wherein the botulinum neurotoxin is type E.

5. The method of claim 1 wherein the botulinum neurotoxin is type A.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRECTIVE ASSIGNMENT TO RE-RECORD ASSIGNMENT PREVIOUSLY RECORDED TO CORRECT BR, MITCHELL F. TO BRIN, MITCHELL F. PREVIOUSLY RECORDED ON REEL 027217 FRAME 0649. ASSIGNOR(S) HEREBY CONFIRMS THE PLEASE SEE ATTACHED ASSIGNMENT AND COVERSHEET. Recorded Dec 6, 2011
From: AURORA, SHEENA K.; TURKEL, CATHERINE C.; BRIN, MITCHELL F.
To: ALLERGAN, INC.
Reel/Frame 027334/0164 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2011
From: AURORA, SHEENA K.; TURKEL, CATHERINE C.; BR, MITCHELL F.
To: ALLERGAN, INC.
Reel/Frame 027217/0649 →
Continuity (3)
Provisional Application 61319230 · Mar 30, 2010
Provisional Application 61320667 · Apr 2, 2010
Related Publication 20120053126A1 · Mar 1, 2012